Du är här

2014-04-07

Novartis International AG: Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia

Novartis International AG / Novartis and Malaria No More provide two million
antimalarial treatments tochildren in Zambia . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
* One million antimalarial treatments donated by Novartis, matching one
million treatments funded through Malaria No More's Power of One campaign

* Power of One enables the public to fund malaria tests and treatments for
children in Africa through online and mobile technology

* Today marks World Health Day, focusing on vector-borne diseases, of which
malaria is the most deadly[1]

Basel, Switzerland, April 7, 2014
- Novartis announced today that two million treatments of its pediatric
antimalarial are arriving in Zambia thanks to the ongoing efforts of the
company in collaboration with Malaria No More's Power of One campaign. Zambia
is the first beneficiary country of this campaign sponsored by Novartis. One
million treatments of Coartem®Dispersible have been funded through public
donations and Novartis matched these with a further one million treatments.
These antimalarials will reduce the disease burden in Zambia, which accounts
for up to 40% of infant mortality in that country[2].

"Although the incidence of malaria has decreased, the disease still kills a
child every minute in Africa," said Joseph Jimenez, CEO of Novartis. "Our
commitment to Power of One reflects our company's long-term efforts to fight
malaria and Novartis remains dedicated to controlling and ultimately
eliminating this deadly disease."

Power of One is a global digital fundraising campaign that enables people
around the world to help end child deaths from malaria, a preventable and
treatable disease. This fatal disease has been recognized by the World Health
Organization as a priority area of public health. This year's World Health
Day focuses on vector-borne diseases, and malaria is the most deadly[1].

The campaign, which launched to the public in September 2013, uses social,
mobile, and e-commerce technologies, enabling the public to purchase
treatments for children in Zambia. Donors are able to share information with
their social networks and encourage friends to donate.

"One and a half million treatments are already on the ground in Zambia thanks
to the Power of One campaign, with a further 500,000 anticipated in the
coming weeks," said Martin Edlund, CEO, Malaria No More. "Power of One is
resonating with the general public, and their donations will help us ensure
that children in Zambia will have access to the treatment they need."

Novartis is supporting the campaign financially and has pledged to match up to
1 million treatments funded by the public every year through 2015. For more
than a decade, the Novartis Malaria Initiative has worked to improve access
to treatment, help communities deliver better healthcare and has invested in
research and development into the next generation of antimalarials. Since
2009, Novartis has delivered over 600 million treatments, of which more than
200 million were treatments developed specifically for children, without
profit to malaria-endemic countries. Never before have so many pediatric
treatments been distributed in such a short timeframe to children suffering
from malaria[3].

About Power of One
Malaria No More's Power of One campaign offers the global public and
corporations the opportunity to help end malaria deaths one dollar and one
child at a time. Every dollar donated funds a full treatment course for a
child diagnosed with malaria in Africa. Malaria No More is grateful for the
support and contributions of Power of One partners: Novartis, Alere, the
Zambian Government, 21st Century Fox, AGFUND, AHAlife.com, the Bill&Melinda
Gates Foundation, Causes.com, Havas Worldwide, John Snow, Inc., Newman's Own
Foundation, PATH/MACEPA, Peace Corps, Time Warner, Twitter, the United States
President's Malaria Initiative, Venmo, West, and more. Additional information
is available atwww.Po1.org.

About the Novartis Malaria Initiative
The Novartis Malaria Initiative is one of the largest access-to-medicine
programs in the healthcare industry. Moving forward, Novartis is committed to
working towards malaria elimination by driving the development of
next-generation antimalarials, with two new classes of drugs currently in
clinical development. The most advanced compound is in Phase II clinical
trials. For more information, please visit:www.malaria.novartis.com

Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "expects,"
or similar expressions. Such forward-looking statements reflect the current
views of the Group regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results expressed or implied by such
statements. These expectations could be affected by, among other things,
risks and factors referred to in the Risk Factors section of Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date
and does not undertake any obligation to update it in the future.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines
and diagnostic tools, over-the-counter and animal health products. Novartis
is the only global company with leading positions in these areas. In 2013,
the Group achieved net sales of USD 57.9 billion, while R&D throughout the
Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 136,000 full-time-equivalent associates and operate in more
than 140 countries around the world. For more information, please
visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartis.

References
[1] World Health Organization. World Health Day - 7 April
2014.http://www.who.int/campaigns/world-health-day/2014/event/en/[last
accessed February 2014]

[2] Malaria No More.
Zambia.https://secure.malarianomore.org/po1#/pages/zambia[last accessed
February 2014]

[3] Malaria No More. Power of
One.https://secure.malarianomore.org/po1#/pages/about-power-of-one[last
accessed February 2014]

# # #

Novartis Media Relations

-----------------------------------------------------------------------------
|Central media line : |
|+41 61 324 2200 |
|Eric Althoff Nadine Schecker |
| |
| |
|Novartis Global Media Relations Novartis Malaria Initiative Communications |
|+41 61 324 7999 (direct) +41 61 696 8633 (direct) |
|+41 79 593 4202 (mobile) +41 79 682 1326 (mobile) |
|eric.althoff@novartis.com nadine.schecker@novartis.com |
-----------------------------------------------------------------------------

e-mail:media.relations@novartis.com

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis

For questions about the site or required registration, please
contact:journalisthelp@thenewsmarket.com.

Novartis Investor Relations

--------------------------------------------------------------------------------
|Central phone: +41 61 324 7944 |
|Samir Shah +41 61 324 7944 North America: |
|Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 |
|Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257 |
|Isabella Zinck +41 61 324 7188 |
| |
|e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
| |
--------------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/1774786/605072.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#1774786

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.